AC Immune SA EBITDA margin
What is the EBITDA margin of AC Immune SA?
The EBITDA margin of AC Immune SA is 293.05%
What is the definition of EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin of companies in the Health Care sector on NASDAQ compared to AC Immune SA
What does AC Immune SA do?
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Companies with ebitda margin similar to AC Immune SA
- Western Asset Inflation-Linked Income Fund has EBITDA margin of 279.93%
- Banimmo SA has EBITDA margin of 282.01%
- Nuveen New Jersey Municipal Value Fund has EBITDA margin of 284.57%
- Wellness and Beauty Solutions has EBITDA margin of 287.70%
- BP Prudhoe Bay Royalty Trust has EBITDA margin of 288.86%
- First Trust Dynamic Europe Equity Income Fund has EBITDA margin of 289.58%
- AC Immune SA has EBITDA margin of 293.05%
- Norvista Capital has EBITDA margin of 294.05%
- abrdn Japan Equity Fund Inc has EBITDA margin of 294.71%
- Allied Hotel Properties has EBITDA margin of 298.57%
- Gabelli Healthcare & WellnessRx Trust has EBITDA margin of 301.04%
- Nuveen California AMT-Free Quality Municipal Income Fund has EBITDA margin of 301.50%
- Gabelli Global Small and Mid Cap Value Trust has EBITDA margin of 301.61%